Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030

Group 1: HCA Healthcare - HCA Healthcare is a leading hospital chain in the U.S. with 186 hospitals and over 2,000 care centers, demonstrating strong market share growth from 24% in 2012 to 27% a decade later [2][3] - The company has successfully navigated challenges such as managing medical facilities and economic issues, resulting in strong financial performance alongside market share gains [3] - HCA plans to continue investing in facilities and services, targeting a 29% market share by 2030, indicating a proven strategy in a competitive industry [3] Group 2: Vertex Pharmaceuticals - Vertex Pharmaceuticals has a strong portfolio focused on cystic fibrosis treatments, being the only company that markets medicines addressing the underlying causes of the condition [4][5] - The company is expanding beyond cystic fibrosis with the recent approval of Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia, which is expected to contribute significantly to revenue [5] - Vertex is awaiting approval for new products and has ongoing clinical trials, positioning the company for potential clinical successes and better-than-average returns through the end of the decade [5][6]